We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Initial Companies Focused on Breakthrough Applications in Therapeutics, Agriculture, and Molecular Pathology


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Initial Companies Focused on Breakthrough Applications in Therapeutics, Agriculture, and Molecular Pathology "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

Illumina, Inc. today announced the selection of three startup companies for the inaugural Illumina Accelerator funding cycle. The companies are Encoded Genomics, Inc., EpiBiome, Inc., and Xcell Biosciences Inc. The Illumina Accelerator is the world's first business accelerator focused solely on creating an innovation ecosystem for the genomics industry. It is led by Amanda Cashin, Ph.D., who was previously Senior Vice President of Life Science at Alexandria Real Estate Equities, Inc., where she helped lead Alexandria Venture Investments.

"The initial companies in our accelerator rose to the top of a highly competitive application process based on their potential to deliver innovative genomics apps in areas as diverse as healthcare and agriculture. Under Amanda's leadership, Illumina, along with partners Yuri Milner and Silicon Valley Bank, is very excited to work with these entrepreneurs to help them expand the next-generation sequencing market," said Mostafa Ronaghi, Ph.D., Illumina's Senior Vice President and Chief Technology Officer.

The Fall 2014 startups are focused on the following applications:
•    Encoded Genomics, a biopharmaceutical company, is interrogating the human genome for functional elements with therapeutic properties.
•    EpiBiome, an agriculture technology company, is developing bacteriophage compositions to prevent and treat mastitis infections in dairy cattle.
•    Xcell Biosciences, a research tools and diagnostics company, is focused on commercializing its proprietary cell culture solution that enables researchers to easily grow primary cells from patient blood, including cancer and immune cells.

The Illumina Accelerator will provide selected startups with seed investment, business guidance, access to Illumina's sequencing systems and reagents, and fully operational lab space in the San Francisco Bay Area during the six-month cycle.

Applications for the Illumina Accelerator Spring 2015 funding cycle are due by February 16, 2015. To apply, visit www.illumina.com/accelerator.

Advertisement